Page last updated: 2024-11-06

dexamethasone 21-palmitate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dexamethasone 21-palmitate is a synthetic corticosteroid, a long-acting ester of dexamethasone. It is used as a depot injection for the treatment of various inflammatory and allergic conditions. The palmitate ester increases the lipophilicity of the drug, allowing for sustained release from the injection site. Studies have shown that dexamethasone 21-palmitate has a prolonged duration of action compared to dexamethasone. Dexamethasone 21-palmitate is synthesized by esterification of dexamethasone with palmitic acid. Its effects are similar to other corticosteroids, including anti-inflammatory, immunosuppressive, and anti-allergic effects. Dexamethasone 21-palmitate is studied because of its long-acting properties, which make it a suitable treatment option for chronic inflammatory conditions. It is also being investigated for its potential use in other areas, such as cancer treatment and autoimmune disorders.'

dexamethasone 21-palmitate: a liposteroid for treatment of hemophagocytic lymphohistiocytosis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID63044
CHEBI ID31471
SCHEMBL ID93887
MeSH IDM0107708

Synonyms (32)

Synonym
(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl hexadecanoate
dexamethasone palmitate
pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-palmitate
limethason
palmitic acid, 21-ester with 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione
brn 6031847
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-((1-oxohexadecyl)oxy)-, (11beta,16alpha)-
9-fluoro-11,17-dihydroxy-16-methyl-21-((1-oxohexadecyl)oxy)pregna-1,4-diene-3,20-dione (11beta,16alpha)-
dexamethasone palmitate (jan)
14899-36-6
limethason (tn)
D01615
dexamethasone 21-palmitate
[2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] hexadecanoate
601xwn7060 ,
unii-601xwn7060
dexamethasone palmitate [jan]
9-fluoro-11,17-dihydroxy-16-methyl-21-((1- oxohexadecyl)oxy)pregna-1,4-diene-3,20-dione (11.beta.,16.alpha.)-
nova63035
dexamethasone palmitate [who-dd]
nova-63035
S5184
SCHEMBL93887
DTXSID8022903
CHEBI:31471
HY-128922
2-((8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl palmitate
NCGC00522021-01
CS-0102469
Q27263139
MS-30856
AKOS040741625
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (23.53)18.7374
1990's3 (17.65)18.2507
2000's7 (41.18)29.6817
2010's3 (17.65)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.42 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (17.65%)5.53%
Reviews3 (17.65%)6.00%
Case Studies3 (17.65%)4.05%
Observational0 (0.00%)0.25%
Other8 (47.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]